Development of a Procedure for Identification of Biperiden Hydrochloride with Specificity for Triperiden Hydrochloride

N. E. Kuz’mina; S. V. Moiseev; V. I. Krylov; A. A. Kutin; V. A. Yashkir; V. A. Merkulov

doi:10.1007/s11094-018-1749-x

Development of a Procedure for Identification of Biperiden Hydrochloride with Specificity for Triperiden Hydrochloride

Authors: Kuz’mina N.E.¹, Moiseev S.V.¹, Krylov V.I.¹, Kutin A.A.¹, Yashkir V.A.¹, Merkulov V.A.¹
Affiliations:
1. Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation
Issue: Vol 51, No 12 (2018)
Pages: 1106-1110
Section: Article
URL: https://ogarev-online.ru/0091-150X/article/view/244931
DOI: https://doi.org/10.1007/s11094-018-1749-x
ID: 244931

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Biperiden hydrochloride, (1RS)-1-[(1RS, 2SR, 4RS)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl-3-(piperidin-1-yl)prop an-1-ol hydrochloride, is one of the most efficacious cholinolytics. It is used to treat Parkinson’s disease and various types of muscular spasms and to ameliorate uncoordinated muscular movements that can accompany the use of several tranquilizers [1, 2]. Biperiden appears in the vital and essential drug list that was approved by an order of the RF Government [3].